Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2... Diabetes Ther (2018) 9:1477–1490 https://doi.org/10.1007/s13300-018-0452-y ORIGINAL RESEARCH Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study . . . Gian Paolo Fadini Daniele Bottigliengo Federica D’Angelo . . . Franco Cavalot Antonio Carlo Bossi Giancarlo Zatti . . Ileana Baldi Angelo Avogaro On behalf of the DARWIN-T2D Network Received: May 3, 2018 / Published online: June 1, 2018 The Author(s) 2018 Methods: This was a multicenter retrospective ABSTRACT study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide Introduction: DPP-4 inhibitors (DPP4i) and extended release. The primary endpoint was sulfonylureas are popular second-line therapies change from baseline in HbA1c. Secondary for type 2 diabetes (T2D), but there is a paucity endpoints were changes in fasting plasma glu- of real-world studies comparing their effective- cose, body weight, and systolic blood pressure. ness in routine clinical practice. Automated software extracted data from the same clinical electronic chart system at all centers. Propensity score matching (PSM) was Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ used to generate comparable cohorts to perform m9.figshare.6292265. outcome analysis. Results: We included data on http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Therapy Springer Journals

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study

Download PDF
14 pages

Loading next page...
1
 
/lp/springer_journal/comparative-effectiveness-of-dpp-4-inhibitors-versus-sulfonylurea-for-NiKsHZXTu9

References (33)

Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
ISSN
1869-6953
eISSN
1869-6961
DOI
10.1007/s13300-018-0452-y
Publisher site
See Article on Publisher Site

Abstract

Diabetes Ther (2018) 9:1477–1490 https://doi.org/10.1007/s13300-018-0452-y ORIGINAL RESEARCH Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study . . . Gian Paolo Fadini Daniele Bottigliengo Federica D’Angelo . . . Franco Cavalot Antonio Carlo Bossi Giancarlo Zatti . . Ileana Baldi Angelo Avogaro On behalf of the DARWIN-T2D Network Received: May 3, 2018 / Published online: June 1, 2018 The Author(s) 2018 Methods: This was a multicenter retrospective ABSTRACT study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide Introduction: DPP-4 inhibitors (DPP4i) and extended release. The primary endpoint was sulfonylureas are popular second-line therapies change from baseline in HbA1c. Secondary for type 2 diabetes (T2D), but there is a paucity endpoints were changes in fasting plasma glu- of real-world studies comparing their effective- cose, body weight, and systolic blood pressure. ness in routine clinical practice. Automated software extracted data from the same clinical electronic chart system at all centers. Propensity score matching (PSM) was Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ used to generate comparable cohorts to perform m9.figshare.6292265. outcome analysis. Results: We included data on

Journal

Diabetes Therapy – Springer Journals

Published: Jun 1, 2018

There are no references for this article.